Role of PET-CT in the Prediction of Response to Neoadjuvant Treatment

  • David Fuster
  • Maria Cristina Marzola
  • Francesca Pons
  • Giovanni de Manzoni
  • Domenico Rubello
Part of the Updates in Surgery book series (UPDATESSURG)


Even if surgery is still the main therapeutic option in patients with esophageal squamous cell carcinoma (SCC), recent studies have shown that neoadjuvant chemoradiotherapy (CRT) can reduce the incidence of local recurrence and improve the overall survival rate [1, 2, 3].


Esophageal Cancer Esophageal Squamous Cell Carcinoma Standardize Uptake Value Pathologic Response Rate Advanced Esophageal Squamous Cell Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Schmidt M, Bollschweiler E, Dietlein M et al (2009) Mean and maximum standardized uptake values in [18F]FDG-PET for assessment of histopathological response in oesophageal squamous cell carcinoma or adenocarcinoma after radiochemotherapy. Eur J Nucl Med Mol Imaging 36:735–744CrossRefGoogle Scholar
  2. 2.
    Vallböhmer D, Hölscher AH, Schneider PM et al (2010) 18F]-fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemotherapy in gastric cancer. J Surg Oncol 102:135–140PubMedCrossRefGoogle Scholar
  3. 3.
    Shields AF, Mankoff DA, Link JM et al (1998) Carbon-11-thymidine and FDG to measure therapy response. J Nucl Med 39:1757–1762PubMedGoogle Scholar
  4. 4.
    Kluge R, Schmidt F, Caca K et al (2001) Positron emission tomography with [(18)F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer. Hepatology 33:1029–1035PubMedCrossRefGoogle Scholar
  5. 5.
    Westerterp M, Van Westreenen HL, Reitsma JB et al (2005) Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy—systematic review. Radiology 236:841–851PubMedCrossRefGoogle Scholar
  6. 6.
    Rebollo AC, Ramos-Font C, Villegas R et al (2009) 18F-fluorodeoxiglucose positron emission tomography for the evaluation of neoadjuvant therapy response in esophageal cancer: systematic review of the literature. Ann Surg 250:247–254CrossRefGoogle Scholar
  7. 7.
    Jones DR, Parker LA Jr, Detterbeck FC, Egan TM (1999) Inadequacy of computed tomography in assessing patients with esophageal carcinoma after induction chemoradiotherapy. Cancer 85:1026–32PubMedCrossRefGoogle Scholar
  8. 8.
    Weber WA, Ott K, Becker K et al (2001) Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 19:3058–3065PubMedGoogle Scholar
  9. 9.
    Ott K, Fink U, Becker K et al (2003) Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol 21: 4604–4610PubMedCrossRefGoogle Scholar
  10. 10.
    Krause B, Herrmann K, Wieder H, Meyer zum Buschenfelde C (2009) 18F-FDG PET and 18F-FDG PET-CTfor Assessing Response to Therapy in Esophageal Cancer. J Nucl Med 50:89S–96SPubMedCrossRefGoogle Scholar
  11. 11.
    Kim TJ, Kim HY, Lee KW, Kim MS (2009) Multimodality assessment of esophageal cancer: preoperative staging and monitoring of response to therapy. Radiographics 29:403–421PubMedCrossRefGoogle Scholar
  12. 12.
    Ott K, Weber WA, Lordick F et al (2006) Metabolic imaging predicts response, survival and recurrence in adenocarcinomas of the oesophagogastric junction. J Clin Oncol 24:4692–4698PubMedCrossRefGoogle Scholar
  13. 13.
    Lordick F, Ott K, Krause BJ et al (2007) PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 8:797–805PubMedCrossRefGoogle Scholar
  14. 14.
    Malik V, Lucey JA, Duffy GJ et al (2010) Early repeated 18F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus. J Nucl Med 51:1863–1869PubMedCrossRefGoogle Scholar
  15. 15.
    Siersema PD (2007) Pathogenesis, diagnosis and therapeutic possibilities of esophageal cancer. Curr Opin Gastroenterol 23:456–461PubMedCrossRefGoogle Scholar
  16. 16.
    Roedl JB, Harisinghani MG, Colen RR et al (2008) Assessment of treatment response and recurrence in esophageal carcinoma based on tumor length and standardized uptake value on positron emission tomography-computed tomography. Ann Thorac Surg 86:1131–1138PubMedCrossRefGoogle Scholar
  17. 17.
    Flamen P, Lerut A, Van Cutsem E et al (2000) The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer. J Thorac Cardiovasc Surg 120:1085–1092PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2012

Authors and Affiliations

  • David Fuster
  • Maria Cristina Marzola
    • 1
  • Francesca Pons
  • Giovanni de Manzoni
  • Domenico Rubello
  1. 1.Dept. of Nuclear Medicine“Santa Maria della Misericordia” HospitalRovigoItaly

Personalised recommendations